Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Oklo Inc (OKLO) Price & Performance

Novavax IncTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Oklo Inc — how do they compare? Novavax Inc trades at $7.94 (market cap $1.31B), while Oklo Inc trades at $45.74 (market cap $8.74B). The key difference: Oklo Inc is far larger — about 6.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.

NVAXOKLO
Market Cap
$1.31B$8.74B
Sector
HealthTechnology
52-Week High
$11.19$174.14
52-Week Low
$6.22$36.84
Enterprise Value
$889.30M$6.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Oklo Inc

OKLO trades at $45.71, up 2.74% with a bullish technical outlook despite recent volatility. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses (-$105.66M net income in 2025) with negative margins. Analyst consensus remains strongly bullish with a $77.07 price target, though CEO share sales and high cash burn present near-term concerns.

While OKLO shows promising nuclear technology development with recent milestones, investors face substantial execution risks amid widening losses and negative cash flow. The stock offers high growth potential in the emerging nuclear energy sector but requires careful risk management given the pre-profitability stage and volatile price action.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Oklo Inc

Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.

Read more on OKLO